“国家队”扫货ETF逾2000亿元，知名基金经理调仓路径各异

Core Viewpoint - The "national team" has significantly increased its investment in ETFs and equity assets, with an estimated total investment exceeding 207 billion yuan in the first half of the year, reflecting a strategic move to stabilize the A-share market amid increased volatility [1][2][4]. Group 1: National Team's Investment Actions - In response to market fluctuations, the central financial institutions, including Central Huijin and China Guoxin, have actively increased their holdings in ETFs and other equity assets since April [2][3]. - Central Huijin Asset Management has become the largest institutional investor in the Huatai-PB CSI 300 ETF, increasing its holdings from 26.62 billion shares at the end of last year to 37.86 billion shares, raising its shareholding ratio from 29.78% to 40.26% [2][3]. - The total investment in ETFs by the national team in the first half of the year reached approximately 207.27 billion yuan, with significant contributions from various ETFs, including Huatai-PB, China Southern, and E Fund [4][3]. Group 2: Fund Managers' Adjustments - In the second quarter, over 57% of active equity funds increased their stock positions, with some funds raising their equity exposure by more than 30% [5][6]. - Notable fund managers, such as Zhang Kun, have adjusted their portfolios by increasing holdings in liquor stocks despite a general market downturn in the food and beverage sector [6][7]. - Liu Gesong has focused on increasing allocations to Hong Kong stocks and non-bank financials, while fund manager Ge Lan has concentrated on innovative pharmaceuticals, reducing exposure to traditional Chinese medicine and medical devices [7][8]. Group 3: Focus on Innovative Pharmaceuticals - The innovative pharmaceutical sector has attracted significant interest from fund managers, with many increasing their stakes in leading companies within this field [8]. - Ge Lan highlighted the ongoing advancements in innovative drug technologies and the increasing collaboration between domestic companies and multinational pharmaceutical firms, indicating a positive outlook for the sector [8].